Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion's Biosimilar Gets FDA Panel Nod Despite Extrapolation Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee discussion reflects tension between desire for indication-specific efficacy data and recognition of benefits of 351(k) pathway.

You may also be interested in...



Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval

Much like it did for the first biosimilars, US FDA approved Yescarta without an advisory committee, as Novartis' first-in-class CAR-T cell therapy already set the stage for an agency review.

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

Pink Sheet's Drug Review Profile reveals FDA's second biosimilar got hung up on product quality concerns that suggested potential differences between Celltrion's CT-P13 and its reference biologic, Janssen's infliximab.

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

Pink Sheet's Drug Review Profile reveals FDA's second biosimilar got hung up on product quality concerns that suggested potential differences between Celltrion's CT-P13 and its reference biologic, Janssen's infliximab.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel